Application of human pancreatic carcinoid BON cells for receptor-targeted drug development

References

• Anthony CT, Hughey S, Lyons J, Weiss S, Hornick CA, Drouant GJ, Fuselier JA, Coy DH, Murphy WA, Woltering EA. (2004). The effect of drug dose and drug exposure time on the binding, internalization, and cytotoxicity of radiolabeled somatostatin analogs. J Surg Res, 119, 1–13.
   PubMed Web of Science ®Google Scholar
• Baldwin RW. (1985). Monoclonal antibody targeting of anti-cancer agents: Mühlbock memorial lecture. Eur J Cancer Clin Oncol, 21, 1281–1285.
   PubMedGoogle Scholar
• Béhé M, Behr TM. (2002). Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers, 66, 399–418.
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst, 92, 1295–1302.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Senter PD. (2008). Antibody-drug conjugates for cancer therapy. Cancer J, 14, 154–169.
   PubMed Web of Science ®Google Scholar
• Eden PA, Taylor JE. (1993). Somatostatin receptor subtype gene expression in human and rodent tumors. Life Sci, 53, 85–90.
   PubMed Web of Science ®Google Scholar
• Ehrlich P. (1956). The relationship existing between chemical constitution, distribution, and pharmacological action. In: Himmelweite F, Marquardt M, Dale H, eds. The Collected Papers of Paul Ehrlich, Vol. 1. Elmsford, NY: Pergamon Press, pp. 596–618.
   Google Scholar
• Engel JB, Schally AV, Dietl J, Rieger L, Hönig A. (2007). Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm, 4, 652–658.
   PubMed Web of Science ®Google Scholar
• Engel JB, Schally AV, Halmos G, Baker B, Nagy A, Keller G. (2005). Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocr Relat Cancer, 12, 999–1009.
   PubMed Web of Science ®Google Scholar
• Evers BM, Ishizuka J, Townsend CM Jr, Thompson JC. (1994). The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann N Y Acad Sci, 733, 393–406.
   PubMed Web of Science ®Google Scholar
• Feron O. (2010). Tumor-penetrating peptides: a shift from magic bullets to magic guns. Sci Transl Med, 2, 34ps26.
   PubMed Web of Science ®Google Scholar
• FitzGerald D, Pastan I. (1989). Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst, 81, 1455–1463.
   PubMed Web of Science ®Google Scholar
• FitzGerald DJ, Willingham MC, Pastan I. (1986). Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer. Proc Natl Acad Sci USA, 83, 6627–6630.
   PubMed Web of Science ®Google Scholar
• Fuselier JA, Sun L, Woltering SN, Murphy WA, Vasilevich N, Coy DH. (2003). An adjustable release rate linking strategy for cytotoxin–peptide conjugates. Bioorg Med Chem Lett, 13, 799–803.
   PubMed Web of Science ®Google Scholar
• Greenblatt DY, Kunnimalaiyaan M, Chen H. (2007). Raf-1 activation in gastrointestinal carcinoid cells decreases tumor cell adhesion. Am J Surg, 193, 331–335; discussion 335.
   PubMed Web of Science ®Google Scholar
• Guillemard V, Saragovi HU. (2001). Taxane–antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res, 61, 694–699.
   PubMed Web of Science ®Google Scholar
• Hertler AA, Frankel AE. (1989). Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol, 7, 1932–1942.
   PubMed Web of Science ®Google Scholar
• Hofsli E, Thommesen L, Yadetie F, Langaas M, Kusnierczyk W, Falkmer U, Sandvik AK, Laegreid A. (2005). Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells. Br J Cancer, 92, 1506–1516.
   PubMed Web of Science ®Google Scholar
• Hohla F, Buchholz S, Schally AV, Krishan A, Rick FG, Szalontay L, Papadia A, Halmos G, Koster F, Aigner E, Datz C, Seitz S. (2010). Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Lett, 294, 35–42.
   PubMed Web of Science ®Google Scholar
• Horrocks C, Halse R, Suzuki R, Shepherd PR. (2003). Human cell systems for drug discovery. Curr Opin Drug Discov Devel, 6, 570–575.
   PubMed Web of Science ®Google Scholar
• Kamb A. (2005). What’s wrong with our cancer models? Nat Rev Drug Discov, 4, 161–165.
   PubMed Web of Science ®Google Scholar
• Kiaris H, Schally AV, Nagy A, Szepeshazi K, Hebert F, Halmos G. (2001). A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. Eur J Cancer, 37, 620–628.
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495–497.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Mayer RJ. (1999). Carcinoid tumors. N Engl J Med, 340, 858–868.
   PubMed Web of Science ®Google Scholar
• Ling V. (1997). Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol, 40(Suppl.), S3–S8.
   PubMed Web of Science ®Google Scholar
• Magrath IT. (1994). Targeted approaches to cancer therapy. Int J Cancer, 56, 163–166.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Lye KD, Kidd M. (2003). A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 97, 934–959.
   PubMed Web of Science ®Google Scholar
• Moody TW, Mantey SA, Fuselier JA, Coy DH, Jensen RT. (2007). Vasoactive intestinal peptide–camptothecin conjugates inhibit the proliferation of breast cancer cells. Peptides, 28, 1883–1890.
   PubMed Web of Science ®Google Scholar
• Moody TW, Pradhan T, Mantey SA, Jensen RT, Dyba M, Moody D, Tarasova NI, Michejda CJ. (2008). Bombesin marine toxin conjugates inhibit the growth of lung cancer cells. Life Sci, 82, 855–861.
   PubMed Web of Science ®Google Scholar
• Moody TW, Sun LC, Mantey SA, Pradhan T, Mackey LV, Gonzales N, Fuselier JA, Coy DH, Jensen RT. (2006). In vitro and in vivo antitumor effects of cytotoxic camptothecin–bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther, 318, 1265–1272.
   PubMed Web of Science ®Google Scholar
• Nooter K, Stoter G. (1996). Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract, 192, 768–780.
   PubMed Web of Science ®Google Scholar
• Panetta R, Patel YC. (1995). Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci, 56, 333–342.
   PubMed Web of Science ®Google Scholar
• Pastan I, Willingham MC, FitzGerald DJ. (1986). Immunotoxins. Cell, 47, 641–648.
   PubMed Web of Science ®Google Scholar
• Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S. (1999). Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des, 14, 473–486.
   PubMedGoogle Scholar
• Patterson LH, Murray GI. (2002). Tumour cytochrome P450 and drug activation. Curr Pharm Des, 8, 1335–1347.
   PubMed Web of Science ®Google Scholar
• Reubi JC. (2003). Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev, 24, 389–427.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. (2000). Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res, 60, 3105–3112.
   PubMed Web of Science ®Google Scholar
• Schally AV, Nagy A. (1999). Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol, 141, 1–14.
   PubMed Web of Science ®Google Scholar
• Schally AV, Nagy A. (2003). New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci, 72, 2305–2320.
   PubMed Web of Science ®Google Scholar
• Schnirer II, Yao JC, Ajani JA. (2003). Carcinoid—a comprehensive review. Acta Oncol, 42, 672–692.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. (2005). Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 436, 568–572.
   PubMed Web of Science ®Google Scholar
• Shoemaker RH, Scudiero DA, Melillo G, Currens MJ, Monks AP, Rabow AA, Covell DG, Sausville EA. (2002). Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem, 2, 229–246.
   PubMedGoogle Scholar
• Sun B, Schally AV, Halmos G. (2000). The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept, 90, 77–84.
   PubMed Web of Science ®Google Scholar
• Sun L, Coy DH. (2008). Cytotoxic conjugates of peptide hormones for cancer chemotherapy. Drugs Future, 33, 217–223.
   Web of Science ®Google Scholar
• Sun L, Fuselier JA, Coy DH. (2004a). Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents. Drug Deliv, 11, 231–238.
   PubMed Web of Science ®Google Scholar
• Sun L, Mackey LV, Luo J, Fuselier JA, Coy DH. (2008). Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin Med Oncol, 2:491–499.
   PubMedGoogle Scholar
• Sun L, Vasilevich NI, Fuselier JA, Hocart SJ, Coy DH. (2004b). Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg Med Chem Lett, 14, 2041–2046.
   PubMed Web of Science ®Google Scholar
• Sun LC, Luo J, Mackey VL, Fuselier JA, Coy DH. (2007). Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anticancer Drugs, 18, 341–348.
   PubMed Web of Science ®Google Scholar
• Teicher BA. (2009). Antibody–drug conjugate targets. Curr Cancer Drug Targets, 9, 982–1004.
   PubMed Web of Science ®Google Scholar
• Ullah MF. (2008). Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev, 9, 1–6.
   PubMed Web of Science ®Google Scholar
• Xiao D, Wang J, Hampton LL, Weber HC. (2001). The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene, 264, 95–103.
   PubMed Web of Science ®Google Scholar
• Weinstein JN. (2006). Spotlight on molecular profiling: “Integromic” analysis of the NCI-60 cancer cell lines. Mol Cancer Ther, 5, 2601–2605.
   PubMed Web of Science ®Google Scholar